Advertisement

Topics

UroGenRA - Genitourinary cancer array - Biotech, Pharma and Life Science Channel

05:22 EDT 26th September 2017 | BioPortfolio

UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It was designed to detect gains and losses that frequently occur in these three cancer types and that have the potential to differentially diagnose and/or stratify patients to assist and guide clinical management. For kidney cancer, it is specifically designed to classify tumors into the four main types (three malignant, one benign) critical at several levels in patient management: diagnosis of image-guided needle biopsies of small incidentally discovered kidney masses providing rationale for surgical/non-surgical management,  diagnosis in patients with larger neoplasms to stratify for risks of local or regionally advanced disease that can be factored in to treatment selection recommendations (i.e., extent of surgical intervention, less invasive options or ablation), in those with metastatic disease, where drug trials are currently based on post-surgical tumor diagnosis, and potentially in the diagnosis of the so-called morphologically “unclassified” renal cancers. Additionally within the predominant subtype, clear cell renal cell carcinoma, prognostication is feasible based on the presence/absence of gain and loss of certain genomic regions. For prostate cancer, UroGenRA, has the potential to assess prostate core/needle biopsy genomic variability, to identify biomarker for inclusion in nomograms for assessment of risk of biochemical recurrence, to assess radiocurability and treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. For bladder cancer, UroGenRA has application in identifying tumors most likely to recur, and of muscle-invasive lesions those most likely to benefit from treatment.

Source: http://cancergenetics.com/cgi-research/cgh-microarray/ UroGenRA is a Registered Trademark of CGI

PubMed Articles [16707 Associated PubMed Articles listed on BioPortfolio]

Analysis of Chromosomal Alterations in Urothelial Carcinoma.

Here, we describe the use of complementary techniques applicable to different types of samples to analyze chromosomal alterations in urothelial carcinoma. By a conventional chromosome analysis on fres...

A Versatile Assay for Detection of Aberrant DNA Methylation in Bladder Cancer.

Urothelial carcinoma of the bladder is one of the most common malignancies in the industrialized world, mainly caused by smoking and occupational exposure to chemicals. The favorable prognosis of earl...

Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel.

Molecular subtypes of bladder cancer (BC) can be determined by relatively small immunohistochemistry panels both for non-muscle invasive (NMI) and muscle invasive (MI) tumors. For analysis of NMI tumo...

Defining the Pathways of Urogenital Schistosomiasis-Associated Urothelial Carcinogenesis through Transgenic and Bladder Wall Egg Injection Models.

Urogenital schistosomiasis (infection with Schistosoma haematobium) is a major cause of bladder carcinogenesis. However, the exact mechanisms of the sequelae leading up to the development of bladder c...

Detection of APOBEC3 Proteins and Catalytic Activity in Urothelial Carcinoma.

Members of the APOBEC3 (A3) family of enzymes were shown to act in an oncogenic manner in several cancer types. Immunodetection of APOBEC3A (A3A), APOBEC3B (A3B), and APOBEC3G (A3G) proteins is partic...

Urothelial Carcinoma Stem Cells: Current Concepts, Controversies, and Methods.

Cancer stem cells are defined as a self-renewing and self-protecting subpopulation of cancer cells able to differentiate into morphologically and functionally diverse cancer cells with a limited lifes...

Spheroid Cultures of Primary Urothelial Cancer Cells: Cancer Tissue-Originated Spheroid (CTOS) Method.

Increasingly, it has been recognized that studying cancer samples from individual patients is important for the development of effective therapeutic strategies and in endeavors to overcome therapy res...

Patient-Derived Bladder Cancer Xenografts.

Patient-derived xenograft (PDX ) tumors are models developed by direct transplant of human tumors into immune-compromised hosts such as nude mice. These models retain the histological and genetic char...

The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model.

Urinary bladder cancer (UBC) is a common and complex malignancy, with a multifactorial etiology, like environmental factors, such as cigarette smoking, occupational exposure, and genetic factors.UBC e...

Orthotopic Mouse Models of Urothelial Cancer.

Orthotopic mouse models of urothelial cancer are essential for testing novel therapies and molecular manipulations of cell lines in vivo. These models are either established by orthotopic inoculation ...

News Articles [13501 Associated News Articles listed on BioPortfolio]

Glythera Licenses Novel Payload Class from Cancer Research UK for the Development of Next-Generation Antibody Drug Conjugates

Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor programme for the development of ADCs conjugated using its highly stable conjugation p...

SYNERGYS Announces Phase 1 SBIR Grant Award From National Institutes of Health

Grant will support development of Vasculogenic Mimicry-blocking Antibody Fusion products for Triple Negative Breast Cancer Synergys Biotherapeutics, a preclinical stage...

Respected NYC Dermatologist Comments on New Research into Melanoma

Dr. Susan Bard, one of the top dermatologists and Mohs surgeons in Manhattan frequently sees people with skin cancer. Based on results from two international drug trials a combination of new treatment...

Mesothelioma Awareness Day: How research is tackling the deadly legacy of asbestos

Science blog The UK had a lot to do to pick itself up after the devastation of World War II. And asbestos, then a wonder insulation material, had a big part to play. Being both heat and fire resist...

Review finds no increased cancer risk for people taking oral diabetes medication

People taking a new oral medication for Type 2 diabetes can breathe a sigh of relief concerning suspicions they might be at an increased risk for many types of cancer, according to Indiana University ...

Pioneering ‘precision’ radiotherapy boosts prostate cancer survival

A high-tech form of radiotherapy that shapes radiation beams to tumours can dramatically improve outcomes for patients with prostate cancer, long-term clinical trial results show. As many as 71 per c...

Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE Immunotherapeutics Candidates’ Advancement into ...

Breast surgeons exert 'enormous influence' on patients’ choices

(Reuters Health) - Breast cancer surgeons play a big role in deciding whether women with early-stage breast cancer undergo a controversial operation to have both breasts removed, even when cancer is f...

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 Pipeline Review, H2 2017 [Report Updated: 29082017] Prices from USD $3500

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10 Pipeline Review, H2 2017SummaryAccording to the ...

Amid Cash Crunch, Genocea to Dump Herpes Vaccine, Focus on Cancer Work

Genocea Biosciences was able to go from startup to publicly traded company, in part, because of the early progress it made developing an experimental vaccine for genital herpes. Yet the Cambridge, MA,...

Events [0 Results]

None

Companies [694 Associated Companies listed on BioPortfolio]

Synergys Biotherapeutics

Synergys is an early stage company developing multifunctional anti-vascularization antibody drugs targeting VEGF-alternative pathways. The Company’s most advanced product can...

NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company developing novel drugs and functional genomics solutions with a primary focus on cancer.The successful completion of the Human Genome Projec...

BioSensics

BioSensics is a research and product development company specializing in wearable sensors for healthcare, offering innovative monitoring solutions for telehealth, aging-in-place, ...

Celcuity Inc.

We are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer ...

Siris Medical Inc.

Siris Medical empowers clinicians to achieve efficient high-quality cancer treatment decisions. It has commercialized the first FDA 510(k) cleared artificial intelligence decision...

NanOlogy, LLC

NanOlogy, LLC (www.nanology.us) is a company formed by DFB Pharmaceuticals, LLC of Fort Worth, TX, CritiTech, Inc. of Lawrence, KS, and US Biotest, Inc. of San Luis Obispo,...

PharmaCyte Biotech, Inc.

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation...

Notable Labs

Notable Labs’ mission is to change the way cancer is treated, which starts with putting patients first. The company is developing a personalized treatment service for people ...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion d...

Mommy & Me Cancer Foundation

Clinical Trials [6469 Associated Clinical Trials listed on BioPortfolio]

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

This research study is studying a combination of drugs as a possible treatment for EGFR mutation-positive lung cancer. The drugs involved in this study are: - EGF816 - ...

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

FORCE is a randomized home-based resistance training/strength training (RT) intervention study for Stage II and III colon cancer patients undergoing chemotherapy. Participants will be 180...

Pilot Study Evaluating a Perioperative E-follow-up Protocol in Patients With Ambulatory Surgery for Breast Cancer

This is a monocentric, prospective cohort study evaluating the feasibility of a perioperative e-follow-up protocol in patients with ambulatory surgery for breast cancer. This protocol wil...

Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients

The goal of this study is to estimate the efficacy of Penguin cold caps in preventing or reducing hair loss in patients receiving (neo)adjuvant chemotherapy (one of four common regimens) f...

Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer

The purpose of this study is to see if eating vitamin D, omega 3 and turmeric (curcumin) slows the growth of prostate cancer in men on active surveillance.

Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness

The North Carolina-Louisiana Prostate Cancer Project is a population-based case-only study of over 2,000 men newly diagnosed with prostate cancer designed to address racial differences in ...

RCT of Laser Therapy for GSM

The aim of the current study is to assess whether the CO2-laser results in superior alleviation of GSM symptoms compare to Er:YAG-laser. Specifically, we will compare objective and subject...

A Study of Efficacy, Safety and Pharmacokinetics of BCD-100 Monotherapy as Second Line Treatment of Patients With Non-small Cell Lung Cancer

International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line th...

A Safety Study of Enfortumab Vedotin Plus Immune Checkpoint Inhibitor Therapy for Patients With Urothelial Bladder Cancer (EV-103)

This is a study that will test how an experimental drug (enfortumab vedotin) combined with a kind of anticancer drug called an immune checkpoint inhibitor (CPI) affects patients with cance...

Multi-center Study on Children's and Adolescents' Medulloblastoma Molecular Subgroups in China

Recently, diagnosis and treatments for medulloblastoma becomes more complicated than before since the new World Health Organization (WHO) diagnosis criteria has put molecular marker onto a...

Videos

None available.

Medical and Biotech [MESH] Definitions

The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.

A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

A genus of gram-negative, aerobic, coccoid bacteria whose organisms are part of the normal flora of the oropharynx, nasopharynx, and genitourinary tract. Some species are primary pathogens for humans.

A contiguous gene syndrome associated with hemizygous deletions of chromosome region 11p13. The condition is marked by the combination of WILMS TUMOR; ANIRIDIA; GENITOURINARY ABNORMALITIES; and MENTAL RETARDATION.

Quick Search
Advertisement
 

Relevant Topics

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Renal disease
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...

review and buy UroGenRA - Genitourinary cancer array market research data and corporate reports here

Channels Quicklinks